NovaBay Pharmaceuticals (NBY) Competitors $0.67 +0.02 (+3.24%) As of 03:57 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock NBY vs. PRPH, ALLR, MTEX, EQ, ERNA, PMN, LPTX, BFRG, SNPX, and NEUPShould you be buying NovaBay Pharmaceuticals stock or one of its competitors? The main competitors of NovaBay Pharmaceuticals include ProPhase Labs (PRPH), Allarity Therapeutics (ALLR), Mannatech (MTEX), Equillium (EQ), Ernexa Therapeutics (ERNA), Promis Neurosciences (PMN), Leap Therapeutics (LPTX), Bullfrog AI (BFRG), Synaptogenix (SNPX), and Neuphoria Therapeutics (NEUP). These companies are all part of the "pharmaceutical products" industry. NovaBay Pharmaceuticals vs. Its Competitors ProPhase Labs Allarity Therapeutics Mannatech Equillium Ernexa Therapeutics Promis Neurosciences Leap Therapeutics Bullfrog AI Synaptogenix Neuphoria Therapeutics NovaBay Pharmaceuticals (NYSE:NBY) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment. Does the media prefer NBY or PRPH? In the previous week, ProPhase Labs had 4 more articles in the media than NovaBay Pharmaceuticals. MarketBeat recorded 4 mentions for ProPhase Labs and 0 mentions for NovaBay Pharmaceuticals. ProPhase Labs' average media sentiment score of 0.63 beat NovaBay Pharmaceuticals' score of 0.00 indicating that ProPhase Labs is being referred to more favorably in the news media. Company Overall Sentiment NovaBay Pharmaceuticals Neutral ProPhase Labs Positive Do institutionals & insiders believe in NBY or PRPH? 23.3% of NovaBay Pharmaceuticals shares are held by institutional investors. Comparatively, 9.5% of ProPhase Labs shares are held by institutional investors. 0.1% of NovaBay Pharmaceuticals shares are held by company insiders. Comparatively, 9.6% of ProPhase Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is NBY or PRPH more profitable? ProPhase Labs has a net margin of 0.00% compared to NovaBay Pharmaceuticals' net margin of -102.72%. ProPhase Labs' return on equity of -184.38% beat NovaBay Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets NovaBay Pharmaceuticals-102.72% -7,293.78% -158.41% ProPhase Labs N/A -184.38%-64.59% Do analysts recommend NBY or PRPH? NovaBay Pharmaceuticals currently has a consensus price target of $0.85, indicating a potential upside of 26.41%. Given NovaBay Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe NovaBay Pharmaceuticals is more favorable than ProPhase Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NovaBay Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00ProPhase Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, NBY or PRPH? NovaBay Pharmaceuticals has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of -0.41, indicating that its share price is 141% less volatile than the S&P 500. Which has stronger valuation & earnings, NBY or PRPH? NovaBay Pharmaceuticals has higher revenue and earnings than ProPhase Labs. ProPhase Labs is trading at a lower price-to-earnings ratio than NovaBay Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovaBay Pharmaceuticals$9.78M0.40-$9.64M-$53.72-0.01ProPhase Labs$6.77M2.86-$53.36M-$1.26-0.37 SummaryNovaBay Pharmaceuticals and ProPhase Labs tied by winning 8 of the 16 factors compared between the two stocks. Get NovaBay Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NBY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NBY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBY vs. The Competition Export to ExcelMetricNovaBay PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$3.91M$776.90M$5.70B$21.12BDividend YieldN/A4.84%4.69%3.60%P/E Ratio-0.011.4028.0728.44Price / Sales0.4025.35448.5760.38Price / CashN/A19.5636.2222.92Price / Book0.166.798.664.69Net Income-$9.64M-$4.32M$3.25B$995.51M7 Day Performance1.42%1.33%4.20%1.64%1 Month Performance17.22%3.74%10.82%5.92%1 Year Performance-65.34%8.18%34.70%11.50% NovaBay Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBYNovaBay Pharmaceuticals1.5706 of 5 stars$0.67+3.2%$0.85+26.4%-69.8%$3.91M$9.78M-0.0130Gap UpPRPHProPhase Labs0.3854 of 5 stars$0.40+10.3%N/A-86.4%$15.18M$6.77M0.00130Gap UpALLRAllarity Therapeutics0.7302 of 5 stars$0.97-2.3%N/A-81.0%$15.03MN/A0.0010Positive NewsMTEXMannatech1.0455 of 5 stars$8.08+2.8%N/A+11.0%$14.94M$115.04M-80.80250News CoverageGap DownEQEquillium2.9663 of 5 stars$0.41-0.2%$3.00+624.5%-58.4%$14.83M$41.10M-1.0640Positive NewsGap UpERNAErnexa Therapeutics1.1012 of 5 stars$1.96-1.0%N/A-92.7%$14.58M$580K-0.2410Positive NewsGap UpPMNPromis Neurosciences2.9631 of 5 stars$1.12+154.5%$4.33+286.9%-56.9%$14.39MN/A-22.405News CoverageAnalyst RevisionHigh Trading VolumeLPTXLeap Therapeutics2.1067 of 5 stars$0.34-1.5%$3.38+895.6%-82.7%$14.26MN/A-0.2040Positive NewsGap DownBFRGBullfrog AI0.417 of 5 stars$1.50-0.7%N/A-43.4%$14.22M$60K-1.854High Trading VolumeSNPXSynaptogenix0.0429 of 5 stars$10.11+7.6%N/A+130.6%$14.05MN/A-1.004High Trading VolumeNEUPNeuphoria Therapeutics2.1992 of 5 stars$7.70+3.4%$21.00+172.7%N/A$14.01M$10K0.00N/A Related Companies and Tools Related Companies PRPH Alternatives ALLR Alternatives MTEX Alternatives EQ Alternatives ERNA Alternatives PMN Alternatives LPTX Alternatives BFRG Alternatives SNPX Alternatives NEUP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NBY) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovaBay Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NovaBay Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.